Trial Profile

Phase 1 Clinical trial of BGE-102 for diseases associated with neuroinflammation such as Obesity.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BGE 102 (Primary)
Indications Inflammation; Obesity
Focus Adverse reactions; First in man
Sponsors BioAge Labs

Most Recent Events

21 Apr 2026 Results presented in the BioAge Labs Media Release.
24 Mar 2026 According to BioAge Labs Media release, full Phase 1 data are anticipated in the first half of 2026.
12 Jan 2026 Results(additional positive interim data from multiple ascending dose (MAD) ) pesneted at BioAge Labs Media release .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com